Gilead Sciences said Monday that a large clinical trial of its drug Trodelvy achieved its primary goal of delaying tumor growth in women with the most common form of breast cancer.
But Gilead chose not to provide any specific data from the study. It would also not even say whether the Trodelvy study results were clinically meaningful for women with HR-positive, HER2-negative breast cancer, despite reaching statistical significance.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
